Trombosis venosa portal en la cirrosis hepática
DOI:
https://doi.org/10.52784/27112330.139Palabras clave:
trombosis, vena porta, cirrosis hepática, anticoagulantes, derivación portosistémica intrahepática transyugular.Resumen
La trombosis de la vena porta (TVP) se define como una oclusión parcial o completa de la luz de la vena porta o sus afluentes por la formación de trombos. La etiología de la formación de TVP en un hígado cirrótico parece ser multifactorial, y presenta una prevalencia de 1,3% a 9,8%. La fisiopatología de la TVP en pacientes con cirrosis aún no se comprende completamente, pero se sabe que existe una disminución de la síntesis tanto de factores procoagulantes como de anticoagulantes, que asociados a factores de riesgo locales o sistémicos, favorecen el predominio de los procoagulantes que causan la trombosis. Establecer el momento de la instauración de la trombosis y el nivel anatómico dentro del sistema venoso espleno-mesentérico, son aspectos fundamentales para estimar el pronóstico y ayudar a la toma de decisiones terapéuticas. A pesar de que hasta la fecha no se ha publicado un consenso sobre su profilaxis o tratamiento en la cirrosis hepática, y existen muchas controversias con respecto al manejo óptimo de la TVP, se han observado beneficios generales de la anticoagulación con heparina de bajo peso molecular en pacientes con cirrosis hepática, en particular en aquellos con TVP aguda. El objetivo de esta revisión es explorar los temas más relevantes al momento de abordar un paciente con cirrosis hepática y TVP.
Descargas
Referencias bibliográficas
Basit SA, Stone CD, Gish R. Portal vein thrombosis. Clin Liver Dis 2015;19:199-221. https://doi.org/10.1016/j.cld.2014.09.012.
Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 2018;31:315-329. https://doi.org/10.20524/aog.2018.0245.
Trebicka J, Strassburg CP. Etiology and complications of portal vein thrombosis. Visc Med 2014;30:375-380. https://doi.org/10.1159/000369987.
Harding DJ, Perera MT, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol 2015;21:6769-6784. https://doi.org/10.3748/wjg.v21.i22.6769.
Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl 2015;21:1016-1021. https://doi.org/10.1002/lt.24134.
Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006;12:2115-2119. https://doi.org/10.3748/wjg.v12.i13.2115.
Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis 2019;39:195-208. https://doi.org/10.1055/s-0039-1679934.
Chen H, Turon F, Hernández-Gea V, Fuster J, Garcia-Criado A, Barrufet M, et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liver Transpl 2016;22:352-365. https://doi.org/10.1002/lt.24387.
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2020. [Epub ahead of print] 20 de noviembre de 2020. https://doi.org/https://doi.org/10.1002/hep.31646.
Sarin SK, Philips CA, Kamath PS, Choudhury A, Maruyama H, Nery FG, et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology 2016;151:574-577. https://doi.org/10.1053/j.gastro.2016.08.033.
Artaza T, Lopes M, Romero M, Sánchez JJ, De la Cruz G, González C, et al. Non-malignant portal vein thrombosis in liver cirrhosis: Diagnosis and treatment. EMJ Hepatol 2016;4:103-110.
Loudin M, Ahn J. Portal vein thrombosis in cirrhosis. J Clin Gastroenterol 2017;51:579-585. https://doi.org/10.1097/mcg.0000000000000834.
Fimognari FL, Violi F. Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 2008;3:213-218. https://doi.org/10.1007/s11739-008-0128-0.
Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-697. https://doi.org/10.1136/gut.2004.042796.
Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015;61:660-667. https://doi.org/10.1002/hep.27546.
Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 2019;156:1582-1599. https://doi.org/10.1053/j.gastro.2019.01.265.
Teng F, Sun K-Y, Fu Z-R. Tailored classification of portal vein thrombosis for liver transplantation: Focus on strategies for portal vein inflow reconstruction. World J of Gastroenterol 2020;26:2691-2701. https://doi.org/10.3748/wjg.v26.i21.2691.
Yerdel MA, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000;69:1873-1881. https://doi.org/10.1097/00007890-200005150-00023.
Bhangui P, Lim C, Levesque E, Salloum C, Lahat E, Feray C, et al. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation. J Hepatol 2019;71:1038-1050. https://doi.org/10.1016/j.jhep.2019.08.012.
Ma J, Yan Z, Luo J, Liu Q, Wang J, Qiu S. Rational classification of portal vein thrombosis and its clinical significance. PloS one 2014;9:112501. https://doi.org/10.1371/journal.pone.0112501.
Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. https://doi.org/10.1016/j.jhepr.2019.12.001.
Wells D, Brackney A. Acute portal vein thrombosis diagnosed with point-of-care ultrasonography. Clin Pract Cases Emerg Med 2017;1:50-52. https://doi.org/10.5811/cpcem.2016.11.32979.
Margini C, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. Dig Liver Dis 2017;49:113-120. https://doi.org/10.1016/j.dld.2016.11.013.
Hidajat N, Stobbe H, Griesshaber V, Felix R, Schroder RJ. Imaging and radiological interventions of portal vein thrombosis. Acta Radiol 2005;46:336-343. https://doi.org/10.1080/02841850510021157.
Dam L, Klok F, Tushuizen M, Ageno W, Murad S, Haren G, et al. Magnetic resonance thrombus imaging to differentiate acute from chronic portal vein thrombosis. TH open 2020;4:224-230. https://doi.org/10.1055/s-0040-1716716.
Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010;254:154-162. https://doi.org/10.1148/radiol.09090304.
Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol 2019;114:258-266. https://doi.org/10.1038/s41395-018-0421-0.
Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010;42:163-170. https://doi.org/10.1016/j.dld.2009.08.003.
Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP reports : innovation in hepatology 2019;1:227-239. https://doi.org/10.1016/j.jhepr.2019.02.006.
Levi-Sandri GB, Lai Q, Berloco PB, Rossi M. Portal vein thrombosis before liver transplant does not alter postoperative patient or graft survival. Exp Clin Transplant 2014;12:238-240.
Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, et al. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: A narrative review. Adv Ther 2020;37:1910-1932. https://doi.org/10.1007/s12325-020-01307-z.
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016;64:179-202. https://doi.org/10.1016/j.jhep.2015.07.040.
Basili S, Pastori D, Raparelli V, Violi F. Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. Therap Adv Gastroenterol 2018;11:1756284818793561. https://doi.org/10.1177/1756284818793561.
Young K, Wong R. Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis. Clin Liver Dis 2017;10:152-156. https://doi.org/https://doi.org/10.1002/cld.679.
Pollack CV, Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-520. https://doi.org/10.1056/NEJMoa1502000.
Connolly SJ, Milling TJ, Jr., Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131-1141. https://doi.org/10.1056/NEJMoa1607887.
O’Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: Coagulation in cirrhosis. Gastroenterology 2019;157:34-43. https://doi.org/10.1053/j.gastro.2019.03.070.
von Köckritz L, De Gottardi A, Trebicka J, Praktiknjo M. Portal vein thrombosis in patients with cirrhosis. Gastroenterol Rep 2017;5:148-156. https://doi.org/10.1093/gastro/gox014.
García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP rep 2020;2:100122-100122. https://doi.org/10.1016/j.jhepr.2020.100122.
Rössle M, Schultheiss M. Timing of the treatment of portal vein thrombosis in patients with cirrhosis: A German hepatologist's perspective. J Transl Int Med 2018;6:11-15. https://doi.org/10.2478/jtim-2018-0003.
Copelan A, Kapoor B, Sands M. Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up. Semin Intervent Radiol 2014;31:235-242. https://doi.org/10.1055/s-0034-1382790.
Sanchez-Ocaña R, Tejedor-Tejada J, Cimavilla-Roman M, de Benito-Sanz M, Asensio-Diaz E, Barrera-Rebollo A, et al. Utility of oral anticoagulants as prophylaxis of recurrent portal thrombosis after liver transplantation. Transplant Proc 2019;51:83-86. https://doi.org/10.1016/j.transproceed.2018.07.014.
Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and meta-analysis. Gastroenterology 2017;153:480-487. https://doi.org/10.1053/j.gastro.2017.04.042.
Barbier CE, Rorsman F, Eriksson L-G, Sangfelt P, Sheikhi R, Vessby J, et al. Placement of a transjugular intrahepatic portosystemic shunt in addition to recanalization of acute and chronic portomesenteric vein occlusions - A retrospective evaluation. Acta Radiol Open 2020;9:2058460120964074. https://doi.org/10.1177/2058460120964074.
Mahmud N. Selection for liver transplantation: Indications and evaluation. Curr Hepatol Rep 2020:1-10. https://doi.org/10.1007/s11901-020-00527-9.
Ozer A, Aktas H, Yilmaz TU, Guner Can M, Gurluler E, Yildiz I, et al. Liver transplant in patients with portal vein thrombosis: The experience of 55 patients. Exp Clin Transplant 2019. [Epub ahead of print] Mayo 8 de 2019. https://doi.org/10.6002/ect.2018.0260.
Al-Dorzi HM, Tamim HM, Aldawood AS, Arabi YM. Venous thromboembolism in critically ill cirrhotic patients: practices of prophylaxis and incidence. Thrombosis 2013;2013:807526-807526. https://doi.org/10.1155/2013/807526.
Aldawood A, Arabi Y, Aljumah A, Alsaadi A, Rishu A, Aldorzi H, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 2011;9:1. https://doi.org/10.1186/1477-9560-9-1.
Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253-1260. https://doi.org/10.1053/j.gastro.2012.07.018.
ClinicalTrials.gov. Multicenter prospective randomized trial of the effect of rivaroxaban on survival and development of complications of portal hypertension in patients with cirrhosis (CIRROXABAN). Barcelona, España: David García Cinca, Hospital Clinic of Barcelona; 2018. Acceso 20 de noviembre de 2020. Disponible en https://clinicaltrials.gov/ct2/show/record/NCT02643212.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
